Back to Hudson Bay Capital Management LP Hudson Bay Capital Management LP

IOVA

12 quarters

Position history for Hudson Bay Capital Management LPHudson Bay Capital Management LP's holdings in Iovance Biotherapeutics, Inc.

No. Hudson Bay Capital exited its IOVA (Iovance Biotherapeutics) position in Q4 2024. Its Q3 2024 13F listed 135,000 shares worth $1.3M. Hudson Bay Capital first reported IOVA in Q1 2022 and held it in 11 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$416,000

Total Shares Change

-25,000

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2024-Q4
Latest
Exited
0
-100.0%
$00.0%$7.40
0
2024-Q3
Decreased
135,000
-46.0%
$1.3M0.0%$9.39
0
2024-Q2
Increased
250,000
+400.0%
$2M0.0%$8.02
42
2024-Q1
Decreased
50,000
-81.8%
$741,0000.0%$14.82
0
2023-Q4
Decreased
275,000
-36.1%
$2.2M0.0%$8.13
0
2023-Q3
Increased
430,200
+56.4%
$2M0.0%$4.55
37
2023-Q2
Decreased
275,000
-44.3%
$1.9M0.0%$7.04
0
2023-Q1
Increased
493,553
+60.2%
$3M0.0%$6.11
38
2022-Q4
Increased
308,000
+208.0%
$2M0.0%$6.39
42
2022-Q3
Unchanged
100,000
0.0%
$958,0000.0%$9.58
0
2022-Q2
Increased
100,000
+300.0%
$1.1M0.0%$11.04
41
2022-Q1
New
25,000
-
$416,0000.0%$16.65
33

Other major holders of IOVA: ARK Investment Management LLC, Franklin Templeton Inc., Avoro Capital Advisors LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used